Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Farmington, Connecticut 06030


The purpose of this study is to examine the effects of essential fatty acid (EFA) supplementation on bone metabolism and frailty in postmenopausal women. The overall hypothesis is that EFA supplementation, via its immunoregulatory and anti-inflammatory activity, will decrease bone turnover, decrease prostaglandins and cytokines associated with bone metabolism and frailty, and change physical outcome measures associated with frailty in postmenopausal women with low bone mass and frailty.

Study summary:

Osteoporosis is a bone thinning disease that results in fractures that occur with minimal trauma. The direct health care costs related to osteoporosis are estimated to be $14 billion per year, comparable to costs in heart failure and asthma. Frailty, or poor physiologic reserve to deal with stressors, is estimated to be 7% in the general population over age 65. The frailty syndrome is characterized by sarcopenia or muscle loss, inflammation, low estrogen, growth hormone and testosterone levels, poor nutrition and disability, and is associated with an increased risk of falls and fracture. Omega-3 fatty acids found in fish oil (eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA)) have been shown to decrease markers of inflammation (cytokines) and decrease death due to heart disease. A number of studies in animals suggest that fish oil (EPA and DHA) supplementation inhibits bone break down, increases calcium absorbed from the diet and enhances calcium in bone. Few studies have assessed the role of n-6 and n-3 fatty acids in the diet in bone disease in humans. As far as we know, no study has evaluated the role of n-3 fatty acids in the frailty syndrome.


Inclusion Criteria: - Postmenopausal women over 65 years old - Spine or hip bone density T score less than -1 - Hand grip strength 2 standard deviations below weight adjusted norms - Able to travel to the clinical sites for follow-up visits Exclusion Criteria: - Any disease that may affect bone metabolism, (i.e Paget's disease, primary hyperparathyroidism) - Cancer of any kind (except basal or squamous cell of skin) in past 5 years. - Use of calcitonin, calcitriol, heparin, phenytoin, phenobarbital, and estrogen in the past 6 months - Use of bisphosphonates, long-term corticosteroids (more than 6 months), methotrexate, or fluoride at any time - Current use of any medication or herbs with anticoagulant or antiplatelet activity, tetracycline, and magnesium or zinc supplementation - Estimated creatinine clearance less than 50 ml/min - History of chronic liver disease or evidence of liver disease on screening - History of hip fracture or known vertebral fracture within the past year - Untreated hypertension or a history of clotting disorders - History of allergy to fish or fish oil



Primary Contact:

Principal Investigator
Anne Kenny, MD
University of Connecticut Center on Aging

Backup Contact:


Location Contact:

Farmington, Connecticut 06030
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: February 04, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.